Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently amended) A composition comprising ~~at least~~ two triglycoside glycoalkaloids ~~of formula I:~~



(I)

~~wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;~~

~~A: represents a radical selected from the following radicals of general formulae (II) to (V):~~



~~each of R^1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR^4;~~

~~each of R^2 is a radical separately selected from the group consisting of hydrogen, amino and OR^4;~~

~~each of R^3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;~~

~~"X" is a radical selected from the group comprising $-CH_2-$, -O- and $-NH_2-$; and~~

~~wherein the compound includes at least one R^4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH_2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates;~~

in ~~wherein the~~a ratio of ~~said glycoalkaloids is~~ between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated.

2. (Currently amended) A composition according to claim 1 wherein the ~~comprising two~~ glycoalkaloids are present in a ratio selected from the group of ratios consisting of approximately: 1:6 - 1:0.5; 1:5; 1:4; 1:3; 1:2; [[,]] 1:1.5 and 1:1.

3. (Currently amended) A composition according to claim 1 wherein the glycoalkaloids are ~~triglycoside glycoalkaloids or~~ solasodine glycosides.

4. (Original) A composition according to claim 1 wherein the glycoalkaloids are selected from the group consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.

5. (Original) A composition comprising about a 1:1 ratio of solamargine and solasonine in isolated form.

6. (Currently amended) A composition comprising two triglycoside glycoalkaloids on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition.

~~at least two glycoalkaloids of formula I wherein:~~

~~either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;~~

~~A: represents a radical selected from the following radicals of general formulae (II) to (V);~~

~~each of R1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR4; each of R2 is a radical separately selected from the group consisting of hydrogen, amino and OR4; each of R3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; "X" is a radical selected from the group comprising $-CH_2-$, $-O-$ and $-NH_2-$; and~~

~~wherein the compound includes at least one R4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH_2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; and~~

~~on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition.~~

7. (Currently amended) A composition according to claim 6 wherein the glycoalkaloids ~~are triglycoside alkaloids and~~ constitute at least 70%-90% of the glycosides in the composition.

8. (Currently amended) A composition according to claim 6, wherein the glycoalkaloids ~~are triglycoside alkaloids and~~ constitute at least 91-95% of the glycosides in the composition.

9. (Currently amended) A composition according to claim 6, wherein the glycoalkaloids ~~are triglycoside alkaloids and~~ constitute at least 96-100% of the glycosides in the composition.

10. (Currently amended) A composition according to claim 6 wherein the ratio of the ~~comprising~~ two glycoalkaloids is~~n~~ a ratio selected from the group of ratios consisting of: 1:5; 1:4; 1:3; 1:2 and 1:1.

11. (Original) A composition according to claim 6 wherein the glycoalkaloids are selected from the group of glycoalkaloids consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.

12. (Original) A composition comprising solamargine and solasonine in a ratio between about 1:6 and 6:1 on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

13. (Original) A composition comprising solamargine and solasonine in a ratio between about 1:4 and 4:1 on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

14. (Original) A composition comprising solamargine and solasonine in a ratio between about 1:3 and 3:1 on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

15. (Original) A composition comprising solamargine and solasonine in a ratio between about 1:2 and 2:1 on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

16. (Original) A composition comprising a 1:1 ratio of solamargine and solasonine on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

17. (Currently amended) A composition consisting essentially of two triglycoside glycoalkaloids.~~at least two glycoalkaloids of formula I wherein:~~

~~either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;~~

~~A: represents a radical selected from the following radicals of general formulae (II) to (V); each of R^1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR^4; each of R^2 is a radical separately selected from the group consisting of hydrogen, amino and OR^4; each of R^3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; "X" is a radical selected from the group comprising CH_2-, -O- and NH_2-; and~~

~~wherein the compound includes at least one R^4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyacetone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH_2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates.~~

18-20. (Canceled)

21. (Currently amended) A composition according to claim 17 wherein the ratio of the glycoalkaloids in the composition ~~consists essentially of two glycoalkaloids in a ratio~~is selected from the group of ratios consisting of: 1:5; 1:4; 1:3; 1:2 and 1:1.

22. (Original) A composition according to claim 17 wherein the glycoalkaloids are selected from the group of glycoalkaloids consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.

23. (Currently amended) A composition consisting essentially of solamargine and solasonine in a ratio between about 1:6 and 6:1~~, 1:4 and 4:1, 1:3 and 3:1 or 1:2 to 2:1~~.

24. (Original) A composition consisting essentially of about a 1:1 ratio of solamargine and solasonine.

25. (Previously presented) A composition according to claim 1 comprising about 0.001% - 5% glycoalkaloids.

26. (Previously presented) A composition according to claim 1 comprising about 10% glycoalkaloids.

27. (Previously presented) A pharmaceutical composition comprising a composition of claim 1 and a pharmaceutically acceptable carrier.

28. (Original) A pharmaceutical composition according to claim 27 adapted for topical delivery.

29. (Original) A pharmaceutical composition according to claim 27 adapted for oral delivery.

30. (Original) A pharmaceutical composition according to claim 27 adapted for parenteral delivery.

31. (Currently amended) A method of treating cancer in a subject comprising the step of administering to the subject an effective amount of a composition comprising ~~at least~~ two triglycoside glycoalkaloids ~~of formula I:~~



(I)

~~wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;~~

~~A: represents a radical selected from the following radicals of general formulae (II) to (V):~~



(II) (III)

(IV) or (V)

~~each of R^1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR^4;~~

~~each of R^2 is a radical separately selected from the group consisting of hydrogen, amino and OR^4;~~

~~each of R^3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;~~

~~"X" is a radical selected from the group comprising $-CH_2-$, -O- and $-NH_2-$; and~~

~~wherein the compound includes at least one R^4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH_2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates;~~

~~wherein the~~ in a ratio of ~~said glycoalkaloids is~~ between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated, or a pharmaceutical composition of claim 27.

32. (Currently amended) A method of treating psoriasis in a subject comprising the step of administering to the subject an effective amount of a composition comprising ~~at least~~ two triglycoside glycoalkaloids ~~of formula I:~~



~~wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;~~

~~A: represents a radical selected from the following radicals of general formulae (II) to (V):~~



~~each of R^1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR^4;~~

~~each of R^2 is a radical separately selected from the group consisting of hydrogen, amino and OR^4;~~

~~each of R^3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;~~

~~"X" is a radical selected from the group comprising CH_2-, -O- and NH_2-; and~~

~~wherein the compound includes at least one R^4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyacetone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH_2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates;~~

in a ~~wherein the~~ ratio of ~~said glycoalkaloids is~~ between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated, or a pharmaceutical composition of claim 27.

33. (Currently amended) A method of treating ~~or~~ abnormal cell growth in a patient comprising the step of administering an effective amount of a composition comprising ~~at least~~ two triglycoside glycoalkaloids ~~of formula I:~~



(I)

~~wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;~~

~~A: represents a radical selected from the following radicals of general formulae (II) to (V):~~



(II) (III) (IV) (V)

~~each of R^1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR^4;~~

~~each of R^2 is a radical separately selected from the group consisting of hydrogen, amino and OR^4;~~

~~each of R^3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;~~

~~"X" is a radical selected from the group comprising CH_2, O and NH_2; and wherein the compound includes at least one R^4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose,~~

~~gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyacetone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH_2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates;~~

in a ~~wherein the~~ ratio of ~~said glycoalkaloids is~~ between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated, or a pharmaceutical composition of claim 27 ~~to the patient~~.

34. (Currently amended) A method of diagnosing abnormal cell growth in a subject comprising the step of applying a composition comprising ~~at least~~ two tryglycoside glycoalkaloids ~~of formula I:~~



~~wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;~~

~~A: represents a radical selected from the following radicals of general formulae (II) to (V):~~



~~each of R^1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR^4;~~

~~each of R^2 is a radical separately selected from the group consisting of hydrogen, amino and OR^4;~~

~~each of R^3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative;~~

~~"X" is a radical selected from the group comprising CH_2-, -O- and NH_2-; and~~

~~wherein the compound includes at least one R^4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH_2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates;~~

in a ~~wherein the~~ ratio of ~~said glycoalkaloids is~~ between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated, or pharmaceutical composition of claim 27 to a test area on said subject and then monitoring said test area for inflammation.

35. (Original) A method according to claim 34 wherein the diagnostic is for skin cancers such as keratoses, basal cell carcinomas, squamous cell carcinomas and melanomas.

36. (Previously presented) A composition of claim 1 further comprising a detectable label.

37. (Currently amended) A method for ~~Use of a composition according to claim 36 for~~ detecting a target cell comprising the steps of applying a ~~the~~ composition according to claim 36 to a sample or a subject and detecting the label.

38. (Previously presented) A composition according to claim 6 comprising about 0.001% - 5% glycoalkaloids.

39. (Previously presented) A composition according to claim 17 comprising about 0.001% - 5% glycoalkaloids.

40. (Previously presented) A composition according to claim 6 comprising about 10% glycoalkaloids.

41. (Previously presented) A composition according to claim 17 comprising about 10% glycoalkaloids.

42. (Previously presented) A pharmaceutical composition comprising a composition of claim 6 and a pharmaceutically acceptable carrier.

43. (Previously presented) A pharmaceutical composition comprising a composition of claim 17 and a pharmaceutically acceptable carrier.

44. (Currently amended) A method of treating cancer in a subject comprising the step of administering to the subject an effective amount of a composition comprising ~~at least~~ two triglycoside glycoalkaloids ~~of formula I wherein:~~

~~either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;~~

~~A: represents a radical selected from the following radicals of general formulae (II) to (V);~~

~~each of R^1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR^4; each of R^2 is a radical separately selected from the group consisting of hydrogen, amino and OR^4; each of R^3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; "X" is a radical selected from the group comprising $-CH_2-$, -O- and $-NH_2-$; and~~

~~wherein the compound includes at least one R^4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH_2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; and~~

on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition~~, or a pharmaceutical composition of claim 27~~.

45. (Canceled)

46. (Currently amended) A method of treating psoriasis in a subject comprising the step of administering to the subject an effective amount of a composition comprising ~~at least~~ two triglycoside glycoalkaloids ~~of formula I wherein:~~

~~either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;~~

~~A: represents a radical selected from the following radicals of general formulae (II) to (V);~~

~~each of R^1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR^4; each of R^2 is a radical separately selected from the group consisting of hydrogen, amino and OR^4; each of R^3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; "X" is a radical selected from the group comprising $-CH_2-$, -O- and $-NH_2-$; and~~

~~wherein the compound includes at least one R^4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH_2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; and~~

on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition~~, or pharmaceutical composition of claim 27~~.

47. (Canceled)

48. (Currently amended) A method of treating ~~or~~ abnormal cell growth in a patient comprising the step of administering an effective amount of a composition comprising ~~at least~~ two triglycoside glycoalkaloids ~~of formula I wherein:~~

~~either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;~~

~~A: represents a radical selected from the following radicals of general formulae (II) to (V);~~

~~each of R^1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR^4; each of R^2 is a radical separately selected from the group consisting of hydrogen, amino and OR^4; each of R^3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; "X" is a radical selected from the group comprising $-CH_2-$, -O- and $-NH_2-$; and~~

~~wherein the compound includes at least one R^4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH_2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; and~~

on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition~~, or pharmaceutical composition of claim 27 to the patient~~.

49. (Canceled)

50. (Currently amended) A method of diagnosing abnormal cell growth in a subject comprising the step of applying a composition comprising ~~at least~~ two triglycoside glycoalkaloids ~~of formula I wherein:~~

~~either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;~~

~~A: represents a radical selected from the following radicals of general formulae (II) to (V);~~

~~each of R^1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR^4; each of R^2 is a radical separately selected from the group consisting of hydrogen, amino and OR^4; each of R^3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; "X" is a radical selected from the group comprising $-CH_2-$, -O- and $-NH_2-$; and~~

~~wherein the compound includes at least one R^4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH_2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; and~~

on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition, ~~or pharmaceutical composition of claim 27~~ to a test area on said subject and then monitoring said test area for inflammation.

51. (Canceled)

52. (Previously presented) A composition of claim 6 further comprising a detectable label.

53. (Previously presented) A composition of claim 17 further comprising a detectable label.

54. (New) A composition consisting essentially of solamargine and solasonine in a ratio between about 1:4 and 4:1.

55. (New) A composition consisting essentially of solamargine and solasonine in a ratio between about 1:3 and 3:1.

56. (New) A composition consisting essentially of solamargine and solasonine in a ratio between about or 1:2 to 2:1.

57. (New) A method according to claim 50 wherein the diagnostic is for skin cancers such as keratoses, basal cell carcinomas, squamous cell carcinomas and melanomas.

58. (New) A method for detecting a target cell comprising the steps of applying a composition according to claim 52 to a sample or a subject and detecting the label.

59. (New) A method of treating cancer in a subject comprising the step of administering to the subject an effective amount of a composition consisting essentially of two triglycoside glycoalkaloids.

60. (New) A method of treating psoriasis in a subject comprising the step of administering to the subject an effective amount of a composition consisting essentially of two triglycoside glycoalkaloids.

61. (New) A method of treating abnormal cell growth in a subject comprising the step of administering to the subject an effective amount of a composition consisting essentially of two triglycoside glycoalkaloids.

62. (New) A method of diagnosing abnormal cell growth in a subject comprising the step of administering to the subject an effective amount of a composition consisting essentially of two triglycoside glycoalkaloids.

63. (New) A method according to claim 62 wherein the diagnostic is for skin cancers such as keratoses, basal cell carcinomas, squamous cell carcinomas and melanomas.

64. (New) A method for detecting a target cell comprising the steps of applying a composition according to claim 53 to a sample or a subject and detecting the label.